20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The platform core will be the customized Artificial Intelligence system integrating multi-target, multi-biomarker, and multi-layer data, to extract different indexes in relation to the customer’s health status. According to the information associated with a patient, including the results coming from two, three, or more types of tests, and the amnestic and phenotypic information, the system will evaluate all the variables necessary to perform the deepest integration. Depending on the types of data, we will use supervised and/or unsupervised approaches and Artificial Intelligence and/or deep learning methods. The development of AI includes the integration of new data connected with mitochondrial dysfunction. The BIOSCIENCE GENOMICS platform will be integrated with an API communication system portal. This approach will help users move the information between the two platforms and avoid redundant information.
